Review/Advance of Neurological Therapeutics (2005). Muscle Disorders.
|
Accession number;06A0654489
|
| Title;Review/Advance of Neurological Therapeutics (2005). Muscle Disorders. |
| Author;
SAHASHI KO
(Aichi Medical Univ., School of Medicine, JPN)
IBI TOORU
(Aichi Medical Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.399-404(2006)
|
| Figure&Table&Reference;REF.77 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Overall review of the therapeutic advances in 2005 about myopathies including myasthenic disorders in the clinical and experimental fields was briefly performed. The myopathies include muscular dystrophies (dystrophinopathy, and the other types of muscular dystrophy), inflammatory myopathy (polymyositis, dermatomyositis, inclusion body myopathy), mitochondrial myopathy, and myasthenic disorders (seropositive and seronegative myasthenia gravis). Medications including genetic approaches by using virus vectors involve a variety of immunosupressants (prednisolone, oxandolone, rituximab, tacrolimus, azathioprine, cyclosporine, cyclophosphamide, methotrexate, .GAMMA.-globulin etc.), antibiotics (streptomicin, gentamicin, etc) and some others (perindopril, L-arginine, isosorbide dinitrate, etc). Those effects are not necessarily dramatic, but the effectiveness of oral use of tacrolimus was interesting in the treatment of inflammatory myopathies and myasthenic diseases. (author abst.) |
|
|
|
Related Articles;
|
|
